Buffalo, New York – Empire Genomics, LLC (www.empiregenomics.com) - a cancer diagnostics company focused on utilizing genetic testing to empower physicians to leverage personalized medicine in the treatment of cancer patients - announced today that it has received approval to offer molecular and cellular tumor marker testing through their Clinical Laboratory Evaluation Program (CLEP) permit from New York State (NYS) allowing for the expansion of its’ test service offerings in the area of molecular oncology.
“The addition of molecular testing solidifies our test menu allowing us to offer a more complete range of testing needed for personalized diagnostics and therapeutics,” shared Dr. John J. Rushton, Empire Genomics’ Chief Operations Officer.
This approval permits Empire to offer testing utilizing the latest in molecular diagnostic technology advances, getting down to the individual DNA sequence. Anthony Johnson, Empire Genomics’ President and CEO states, “This is a testament to the hard work and dedication of our experienced staff and allows us to continually offer the highest quality of testing services to our customers.”
The CLEP seeks to ensure the accuracy and reliability of test results in clinical laboratories located in or accepting specimens from NYS through on-site inspections, proficiency testing and evaluation of the qualifications of personnel of state permit-holding clinical laboratories and blood banks.
About Empire Genomics
Empire Genomics, LLC is a molecular diagnostics firm specializing in oncology. The company offers a wide range of best-in-class services that are used to detect genomic changes. The organization is a global leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, prognosis, and selection of ideal disease therapy.
“The addition of molecular testing solidifies our test menu allowing us to offer a more complete range of testing needed for personalized diagnostics and therapeutics,” shared Dr. John J. Rushton, Empire Genomics’ Chief Operations Officer.
This approval permits Empire to offer testing utilizing the latest in molecular diagnostic technology advances, getting down to the individual DNA sequence. Anthony Johnson, Empire Genomics’ President and CEO states, “This is a testament to the hard work and dedication of our experienced staff and allows us to continually offer the highest quality of testing services to our customers.”
The CLEP seeks to ensure the accuracy and reliability of test results in clinical laboratories located in or accepting specimens from NYS through on-site inspections, proficiency testing and evaluation of the qualifications of personnel of state permit-holding clinical laboratories and blood banks.
About Empire Genomics
Empire Genomics, LLC is a molecular diagnostics firm specializing in oncology. The company offers a wide range of best-in-class services that are used to detect genomic changes. The organization is a global leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, prognosis, and selection of ideal disease therapy.
